The earnings call presented a mix of positive and negative aspects. Highlights included revenue and EBITDA growth, as well as significant debt reduction. However, challenges such as the impact of hurricanes, procedural volume delays, and patient eligibility backlog were noted. Overall, the sentiment is balanced with both encouraging growth and notable obstacles.

Company Guidance

During the Owens & Minor Q3 2024 earnings call, the company provided guidance for the full year, projecting revenue in the range of $10.6 billion to $10.8 billion, adjusted EBITDA between $540 million and $550 million, and adjusted earnings per share of $1.45 to $1.55. The executive team highlighted several factors influencing these projections, including manufacturing supply chain issues, procedural volume impacts due to hurricane-related infrastructure damage, and delays in patient eligibility verification within the Patient Direct segment. Despite these challenges, the company reported mid-single-digit revenue growth in both the Products and Healthcare Services and Patient Direct segments, driven by strong demand in diabetes and sleep supplies. Additionally, Owens & Minor emphasized their commitment to reducing debt, having decreased total debt by nearly $200 million during the quarter. The guidance excludes any potential impacts from the anticipated Rotech Healthcare Holdings acquisition, expected to close in the first half of 2025.

Top Line Growth Across Segments

Achieved top line growth across both segments, particularly with exceptional demand for sleep supplies and diabetes in the Patient Direct segment, and strong same-store sales within Products and Healthcare Services.

Debt Reduction

Reduced total debt by nearly $200 million in the most recent quarter, bringing the total year-to-date debt reduction to approximately $210 million.

Revenue Increase

Revenue for the quarter was $2.7 billion, up 5% compared to the prior year.

Adjusted EBITDA Growth

Adjusted EBITDA was $142 million, up over 5% versus the $135 million reported during the third quarter last year.

Progress with Patient Direct Segment

Delivered mid-single-digit year-over-year top line growth driven by strong demand across served indications, notably in diabetes products and sleep supplies.

---

Owens & Minor (OMI) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

OMI Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Aug 07, 2018	2018 (Q2)	- / 0.32	0.43	-25.58% (-0.11)	―	―
Oct 31, 2018	2018 (Q3)	- / 0.32	0.4	-20.00% (-0.08)	―	―
Feb 19, 2019	2018 (Q4)	- / 0.09	0.35	-74.29% (-0.26)	―	―
May 07, 2019	2019 (Q1)	- / 0.02	0.43	-95.35% (-0.41)	―	―
Aug 07, 2019	2019 (Q2)	- / 0.10	0.32	-68.75% (-0.22)	―	―
Nov 06, 2019	2019 (Q3)	- / 0.22	0.32	-31.25% (-0.10)	―	―
Mar 04, 2020	2019 (Q4)	- / 0.26	0.09	188.89% (+0.17)	―	―
May 06, 2020	2020 (Q1)	- / 0.04	0.02	100.00% (+0.02)	―	―
Aug 04, 2020	2020 (Q2)	- / 0.20	0.1	100.00% (+0.10)	―	―
Nov 02, 2020	2020 (Q3)	- / 0.81	0.22	268.18% (+0.59)	―	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

---

OMI Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Nov 04, 2024	$13.36	$12.00	-10.18%
Aug 02, 2024	$16.42	$16.20	-1.34%
May 03, 2024	$24.51	$18.21	-25.70%
Feb 20, 2024	$21.21	$21.54	+1.56%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

---